Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The p53-independent apoptosis pathway refers to mechanisms of programmed cell death that occur without the involvement of the tumor suppressor protein p53. Triggering events include DNA damage, ribosomal stress, telomere dysfunction, and cytokine signaling (e.g., TNF-α). Key molecular mediators include SLFN11, GCN2 kinase, ZAKα, and the JNK pathway. This pathway serves as a backup mechanism for eliminating damaged or abnormal cells, especially in cancers with TP53 mutations. Disruption of this pathway, such as through loss of SLFN11, can lead to chemoresistance. Targeting this pathway offers potential therapeutic strategies for TP53-mutant tumors.
Various, depending on the specific pathway. Examples include: Activation of JNK pathway, Activation of death receptors (e.g. TNF-alpha receptor), Ribosome stalling and ZAKα-mediated activation of apoptosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on p53-Independent Apoptosis Pathway.